Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-07-2016 | Review – Cancer Research

Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer

Authors: Mei Xue, Wei Chen, Xu Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2016

Abstract

Background

Urothelial cancer associated 1 (UCA1) is a long noncoding RNA (lncRNA) which has gained more attention in recent years due to its aberrant expression in embryogenesis and a broad range of cancer tissues and cells. Importantly, multiple studies have shown that UCA1 plays oncogenic roles in tumor growth and metastasis, and it may act as a potential biomarker and therapeutic target for human cancers. However, the molecular mechanism of UCA1 in cancer initiation, progression and metastasis remains incompletely understood. Thus, gaining a better understanding of the functional mechanism of UCA1 in cancer onset and progression is of the utmost significance for evaluating the potential application of UCA1.

Results and discussion

In this review, we discuss UCA1 expression profiling, isoform, expression regulation, biological role and mechanism for UCA1 tumor-promoting effect. We further discuss the potential clinical application of UCA1 as a promising diagnostic biomarker or therapeutic target for human cancers.

Conclusion

UCA1 functions as an oncogenic lncRNA in several malignancies, and it might become a potential biomarker or therapeutic target for human cancers.

Beyer TA, Weiss A, Khomchuk Y, Huang K, Ogunjimi AA, Varelas X, Wrana JL (2013) Switch enhancers interpret TGF-beta and Hippo signaling to control cell fate in human embryonic stem cells. Cell Rep 5(6):1611–1624. doi:10.1016/j.celrep.2013.11.021 CrossRefPubMed

Broxterman HJ, Gotink KJ, Verheul HM (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12(4–5):114–126. doi:10.1016/j.drup.2009.07.001 CrossRefPubMed

Cao WJ, Wu HL, He BS, Zhang YS, Zhang ZY (2013) Analysis of long non-coding RNA expression profiles in gastric cancer. World J Gastroenterol 19(23):3658–3664. doi:10.3748/wjg.v19.i23.3658 CrossRefPubMedPubMedCentral

Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378. doi:10.1016/j.ejphar.2014.07.025 CrossRefPubMed

Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhattar R, Gingeras TR, Hubbard TJ, Notredame C, Harrow J, Guigo R (2012) The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22(9):1775–1789. doi:10.1101/gr.132159.111 CrossRefPubMedPubMedCentral

Ellis BC, Graham LD, Molloy PL (2014) CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta 1843(2):372–386. doi:10.1016/j.bbamcr.2013.10.016 CrossRefPubMed

Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y (2014) Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J 281(7):1750–1758. doi:10.1111/febs.12737 CrossRefPubMed

Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y, Feng Y, Li L, Wang Y, Liu X, Chen H, Liu XY, Ji H (2012) MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem 287(27):23227–23235. doi:10.1074/jbc.M112.373084 CrossRefPubMedPubMedCentral

Fang Z, Wu L, Wang L, Yang Y, Meng Y, Yang H (2014) Increased expression of the long non-coding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis. Oral Surg Oral Med Oral Pathol Oral Radiol 117(1):89–95. doi:10.1016/j.oooo.2013.09.007 CrossRefPubMed

Ganapathy-Kanniappan S, Geschwind JF (2013) Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 12:152. doi:10.1186/1476-4598-12-152 CrossRefPubMedPubMedCentral

Gilkes DM, Semenza GL, Wirtz D (2014) Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 14(6):430–439. doi:10.1038/nrc3726 CrossRefPubMedPubMedCentral

Giza DE, Vasilescu C, Calin GA (2014) MicroRNAs and ceRNAs: therapeutic implications of RNA networks. Expert Opin Biol Ther 14(9):1285–1293. doi:10.1517/14712598.2014.920812 CrossRefPubMed

Gutschner T, Baas M, Diederichs S (2011) Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases. Genome Res 21(11):1944–1954. doi:10.1101/gr.122358.111 CrossRefPubMedPubMedCentral

Gutschner T, Diederichs S (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9(6):703–719. doi:10.4161/rna.20481 CrossRefPubMedPubMedCentral

Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zornig M, MacLeod AR, Spector DL, Diederichs S (2013) The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73(3):1180–1189. doi:10.1158/0008-5472.CAN-12-2850 CrossRefPubMed

Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458(7235):223–227. doi:10.1038/nature07672 CrossRefPubMedPubMedCentral

Han Y, Liu Y, Zhang H, Wang T, Diao R, Jiang Z, Gui Y, Cai Z (2013) Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long noncoding RNA MALAT1. FEBS Lett. doi:10.1016/j.febslet.2013.10.023

Han Y, Yang YN, Yuan HH, Zhang TT, Sui H, Wei XL, Liu L, Huang P, Zhang WJ, Bai YX (2014) UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology 46(5):396–401. doi:10.1097/PAT.0000000000000125 CrossRefPubMed

Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, Appelbaum L, Kopelman Y, Czerniak A, Hochberg A (2012) Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther 19(6):374–381. doi:10.1038/cgt.2012.10 CrossRefPubMed

Hessels D, Klein GJ, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44(1):8–15CrossRefPubMed

Hiemer SE, Szymaniak AD, Varelas X (2014) The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem 289(19):13461–13474. doi:10.1074/jbc.M113.529115 CrossRefPubMedPubMedCentral

Ho TT, Zhou N, Huang J, Koirala P, Xu M, Fung R, Wu F, Mo YY (2014) Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res 43(3):e17. doi:10.1093/nar/gku1198 CrossRefPubMedPubMedCentral

Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu M, Mo YY (2014) Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis 5:e1008. doi:10.1038/cddis.2013.541 CrossRefPubMedPubMedCentral

Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, Attardi LD, Regev A, Lander ES, Jacks T, Rinn JL (2010) A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142(3):409–419. doi:10.1016/j.cell.2010.06.040 CrossRefPubMedPubMedCentral

Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhauser ML, Ding H, Butty VL, Torrey L, Haas S, Abo R, Tabebordbar M, Lee RT, Burge CB, Boyer LA (2013) Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 152(3):570–583. doi:10.1016/j.cell.2013.01.003 CrossRefPubMedPubMedCentral

Kornfeld JW, Bruning JC (2014) Regulation of metabolism by long, non-coding RNAs. Front Genet 5:57. doi:10.3389/fgene.2014.00057 CrossRefPubMedPubMedCentral

Kumar PP, Emechebe U, Smith R, Franklin S, Moore B, Yandell M, Lessnick SL, Moon AM (2014) Coordinated control of senescence by lncRNA and a novel T-box3 co-repressor complex. Elife. doi:10.7554/eLife.02805 PubMedPubMedCentral

Lee GL, Dobi A, Srivastava S (2011) Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol 8(3):123–124. doi:10.1038/nrurol.2011.10 CrossRefPubMed

Li JY, Ma X, Zhang CB (2014a) Overexpression of long non-coding RNA UCA1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol 7(11):7938–7944PubMedPubMedCentral

Li L, Feng T, Lian Y, Zhang G, Garen A, Song X (2009) Role of human noncoding RNAs in the control of tumorigenesis. Proc Natl Acad Sci USA 106(31):12956–12961. doi:10.1073/pnas.0906005106 CrossRefPubMedPubMedCentral

Li Z, Li X, Wu S, Xue M, Chen W (2014b) Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway. Cancer Sci 105(8):951–955. doi:10.1111/cas.12461 CrossRefPubMedPubMedCentral

Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, Wu F, Mo YY (2013a) LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res 41(9):4976–4987. doi:10.1093/nar/gkt182 CrossRefPubMedPubMedCentral

Liu SP, Yang JX, Cao DY, Shen K (2013b) Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials. Cancer Biol Med 10(3):138–141. doi:10.7497/j.issn.2095-3941.2013.03.003 PubMedPubMedCentral

Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J (2013) Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett 333(2):213–221. doi:10.1016/j.canlet.2013.01.033 CrossRefPubMed

Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M (2007) Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10(1–2):13–29. doi:10.1016/j.drup.2007.01.003 CrossRefPubMed

Matouk I, Raveh E, Ohana P, Lail RA, Gershtain E, Gilon M, De Groot N, Czerniak A, Hochberg A (2013) The increasing complexity of the oncofetal h19 gene locus: functional dissection and therapeutic intervention. Int J Mol Sci 14(2):4298–4316. doi:10.3390/ijms14024298 CrossRefPubMedPubMedCentral

Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, Degroot N, Galun E, Hochberg A (2010) The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta 1803(4):443–451. doi:10.1016/j.bbamcr.2010.01.010 CrossRefPubMed

Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10(3):155–159. doi:10.1038/nrg2521 CrossRefPubMed

Mercer TR, Mattick JS (2013) Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 20(3):300–307. doi:10.1038/nsmb.2480 CrossRefPubMed

Michalik KM, You X, Manavski Y, Doddaballapur A, Zornig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, Boon RA, Dimmeler S (2014) Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 114(9):1389–1397. doi:10.1161/CIRCRESAHA.114.303265 CrossRefPubMed

Mizrahi A, Czerniak A, Ohana P, Amiur S, Gallula J, Matouk I, Abu-Lail R, Birman T, Hochberg A, Levy T (2010) Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report. J Med Case Rep 4:228. doi:10.1186/1752-1947-4-228 CrossRefPubMedPubMedCentral

Nana-Sinkam SP, Croce CM (2011) Non-coding RNAs in cancer initiation and progression and as novel biomarkers. Mol Oncol 5(6):483–491. doi:10.1016/j.molonc.2011.10.003 CrossRefPubMed

Qi P, Du X (2013) The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol 26(2):155–165. doi:10.1038/modpathol.2012.160 CrossRefPubMed

Rorive S, Sandras F, Biskri L, Fossion C, Catteau X, Roumeguere T, Bossche Vanden, Mijatovic T, Salmon I (2009) RT-PCR-based UCA1 expression detection in urine samples as non-invasive reliable method for urothelial cancer diagnosis. EJC Suppl 7(4):28–29. doi:10.1016/S1359-6349(09)72204-9 CrossRef

Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107(6):1053–1062. doi:10.1002/jcb.22214 CrossRefPubMed

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146(3):353–358. doi:10.1016/j.cell.2011.07.014 CrossRefPubMedPubMedCentral

Shen X, Qi P, Du X (2015) Long non-coding RNAs in cancer invasion and metastasis. Mod Pathol 28(1):4–13. doi:10.1038/modpathol.2014.75 CrossRefPubMed

Smaldone MC, Davies BJ (2010) BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Curr Opin Mol Ther 12(5):607–616PubMed

Srivastava AK, Singh PK, Rath SK, Dalela D, Goel MM, Bhatt ML (2014) Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder. Tumour Biol 35(11):11435–11442. doi:10.1007/s13277-014-2474-z CrossRefPubMed

Stephan C, Ralla B, Jung K (2014) Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim Biophys Acta 1846(1):99–112. doi:10.1016/j.bbcan.2014.04.001 PubMed

Tay Y, Rinn J, Pandolfi PP (2014) The multilayered complexity of ceRNA crosstalk and competition. Nature 505(7483):344–352. doi:10.1038/nature12986 CrossRefPubMedPubMedCentral

Tian Y, Zhang X, Hao Y, Fang Z, He Y (2014) Potential roles of abnormally expressed long noncoding RNA UCA1 and Malat-1 in metastasis of melanoma. Melanoma Res 24(4):335–341. doi:10.1097/CMR.0000000000000080 CrossRefPubMed

Tsai MC, Spitale RC, Chang HY (2011) Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 71(1):3–7. doi:10.1158/0008-5472.CAN-10-2483 CrossRefPubMedPubMedCentral

Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, Kwok TT (2010) Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31(3):350–358. doi:10.1093/carcin/bgp181 CrossRefPubMed

Tsang WP, Wong TW, Cheung AH, Co CN, Kwok TT (2007) Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA 13(6):890–898. doi:10.1261/rna.359007 CrossRefPubMedPubMedCentral

Vander HM, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033. doi:10.1126/science.1160809 CrossRef

Wang F, Li X, Xie X, Zhao L, Chen W (2008) UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett 582(13):1919–1927. doi:10.1016/j.febslet.2008.05.012 CrossRefPubMed

Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK (2015a) Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget 6(10):7899–7917CrossRefPubMedPubMedCentral

Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q, Guo H, Yu C (2015b) Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma 62(3):432–438. doi:10.4149/neo_2015_051 CrossRefPubMed

Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q (2010) CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 38(16):5366–5383. doi:10.1093/nar/gkq285 CrossRefPubMedPubMedCentral

Wang KC, Chang HY (2011) Molecular mechanisms of long noncoding RNAs. Mol Cell 43(6):904–914. doi:10.1016/j.molcel.2011.08.018 CrossRefPubMedPubMedCentral

Wang T, Yuan J, Feng N, Li Y, Lin Z, Jiang Z, Gui Y (2014a) Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer. Tumour Biol 35(10):10075–10084. doi:10.1007/s13277-014-2321-2 CrossRefPubMed

Wang X, Gong Y, Jin B, Wu C, Yang J, Wang L, Zhang Z, Mao Z (2014b) Long non-coding RNA urothelial carcinoma associated 1 induces cell replication by inhibiting BRG1 in 5637 cells. Oncol Rep 32(3):1281–1290. doi:10.3892/or.2014.3309 PubMedPubMedCentral

Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW, Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, Zhang Y, Xin DQ, Na YQ, Chen WF (2006) Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res 12(16):4851–4858. doi:10.1158/1078-0432.CCR-06-0134 CrossRefPubMed

Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, Li X (2012) Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol 41(1):276–284. doi:10.3892/ijo.2012.1443 PubMed

Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314CrossRefPubMed

Wu W, Zhang S, Li X, Xue M, Cao S, Chen W (2013) Ets-2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long non-coding RNA, in bladder cancer cells. PLoS One 8(9):e73920. doi:10.1371/journal.pone.0073920 CrossRefPubMedPubMedCentral

Xue M, Li X, Li Z, Chen W (2014a) Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1alpha-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion. Tumour Biol 35(7):6901–6912. doi:10.1007/s13277-014-1925-x CrossRefPubMed

Xue M, Li X, Wu W, Zhang S, Wu S, Li Z, Chen W (2014b) Upregulation of long non-coding RNA urothelial carcinoma associated 1 by CCAAT/enhancer binding protein alpha contributes to bladder cancer cell growth and reduced apoptosis. Oncol Rep 31(5):1993–2000. doi:10.3892/or.2014.3092 PubMedPubMedCentral

Yang C, Li X, Wang Y, Zhao L, Chen W (2012) Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene 496(1):8–16. doi:10.1016/j.gene.2012.01.012 CrossRefPubMed

Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F, Sun SH (2013a) Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 49(6):1083–1096. doi:10.1016/j.molcel.2013.01.010 CrossRefPubMed

Yang F, Xue X, Bi J, Zheng L, Zhi K, Gu Y, Fang G (2013b) Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol 139(3):437–445. doi:10.1007/s00432-012-1324-x CrossRefPubMed

Yang F, Zhang H, Mei Y, Wu M (2014) Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect. Mol Cell 53(1):88–100. doi:10.1016/j.molcel.2013.11.004 CrossRefPubMed

Zhang Q, Su M, Lu G, Wang J (2013a) The complexity of bladder cancer: long noncoding RNAs are on the stage. Mol Cancer 12(1):101. doi:10.1186/1476-4598-12-101 CrossRefPubMedPubMedCentral

Zhang Z, Zhu Z, Watabe K, Zhang X, Bai C, Xu M, Wu F, Mo YY (2013b) Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ 20(11):1558–1568. doi:10.1038/cdd.2013.110 CrossRefPubMedPubMedCentral

Zheng Q, Wu F, Dai WY, Zheng DC, Zheng C, Ye H, Zhou B, Chen JJ, Chen P (2015) Aberrant expression of UCA1 in gastric cancer and its clinical significance. Clin Transl Oncol. doi:10.1007/s12094-015-1290-2

Zhou Y, Zhang X, Klibanski A (2012) MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol 48(3):R45–R53. doi:10.1530/JME-12-0008 CrossRefPubMedPubMedCentral

Title: Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer
Authors: Mei Xue
Wei Chen
Xu Li
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2016
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2042-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Results and discussion

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2016

The relationship of cognitive performance to concurrent symptoms, cancer- and cancer-treatment-related variables in women with early-stage breast cancer: a 2-year longitudinal study

Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia

Phase I trial of dovitinib (TKI258) in recurrent glioblastoma

High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes

Exploring an herbal “wonder cure” for cancer: a multidisciplinary approach

Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage